Apricus Biosciences Announces Corporate Update and First Quarter 2014 Financial Results Conference Call

By GlobeNewswire,  April 28, 2014, 08:00:00 AM EDT


Conference Call and Webcast to be Held Monday, May 12, 2014 at 5:00 p.m. ET

SAN DIEGO, April 28, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that the Company's first quarter financial results will be released after market close on Monday, May 12, 2014. Company management will host a conference call on Monday, May 12, 2014, at 5:00 p.m. ET to discuss these results and other recent corporate highlights.

To participate by telephone, please dial 877-407-9210 (Domestic) or 201-689-8049 (International).  The conference ID number is 13580814.  The live and archived audio webcast can be accessed via the following link: http://www.investorcalendar.com/IC/CEPage.asp?ID=172650 or on the Company's website at www.apricusbio.com.  A replay of the call will be available by dialing 877-660-6853 (Domestic) or 201-612-7415 (International).  The archived webcast will remain available for three months following the live call.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. ( APRI ) is a pharmaceutical company focused on the development and commercialization of novel therapeutics for men's and women's health. The Company's lead product, Vitaros®, for the treatment of erectile dysfunction, is approved in Europe and Canada and will be commercialized by Apricus' marketing partners, which include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. The Company's second generation Vitaros Room Temperature Device is under development and is expected to further enhance the product's commercial value. Femprox®, the Company's product candidate for the treatment of female sexual interest/arousal disorder, has successfully completed an approximately 400-subject proof-of-concept study. The Company is currently seeking a strategic partner for Femprox.

For further information on Apricus, visit http://www.apricusbio.com.

CONTACT: Steve MartinApricus Biosciences
         Chief Financial Officer
         ir@apricusbio.com
         (858) 222-8041

         Angeli Kolhatkar
         Burns McClellan
         Senior Vice President
         akolhatkar@burnsmc.com
         (212) 213-0006

Source: Apricus Biosciences, Inc.

This article appears in: News Headlines

Referenced Stocks: APRI


Latest News Video





Most Active by Volume

Company Last Sale Change Net / %
FB $ 75.19 0.21 ▲ 0.28%
SIRI $ 3.44 0.01 ▼ 0.29%
AAPL $ 97.671 0.64 ▲ 0.66%
F $ 17.62 0.22 ▼ 1.23%
BAC $ 15.59 0.03 ▼ 0.19%
AMAT $ 21.23 0.53 ▼ 2.41%
AMD $ 3.76 0.03 ▲ 0.80%
INTC $ 34.25 unch

As of 7/25/2014, 04:03 PM